Differential Usefulness of Various Markers in the Flow Cytometric Detection of Paroxysmal Nocturnal Hemoglobinuria in Blood and Bone Marrow

Department of Pathology, University of Texas, Southwestern Medical Center, Dallas, TX 75390-9073, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 12/2006; 126(5):781-8. DOI: 10.1309/AT9Y-6WR0-3PX1-K228
Source: PubMed


In this study, we examined the usefulness of various markers on blood cell populations in the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). We also evaluated bone marrow specimens, which generally are considered less suitable than blood owing to variable expression of glycosyl phosphatidylinositol (GPI)-linked antigens during hematopoietic cell differentiation. All 15 patients in our cohort had subpopulations of CD16/CD55-deficient granulocytes and CD14/CD55-deficient monocytes ("PNH clones"). The PNH clone size of granulocytes and monocytes was greater than that of erythrocytes or lymphocytes in the majority of the cases. It is interesting that CD59 showed limited usefulness for detecting PNH+ monocytes. Normal monocytes exhibited significantly dimmer CD59 expression than normal granulocytes. PNH-deficient monocytes expressed only marginally lower CD59, making it a less robust marker for highlighting PNH+ monocytes compared with CD14 or CD55. Finally, our study demonstrated the definitive usefulness of a limited combination of markers (CD16/CD55/CD45/CD14) in detecting GPI-deficient monocytes and granulocytes in bone marrow specimens submitted for flow cytometric evaluation of cytopenias.

Download full-text


Available from: Horatiu Olteanu,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon acquired stem cell disorder associated with periodic hemolytic events. This benign clonal disease is caused by abnormalities of the X-linked phosphatidylinositol glycan class A (PIGA) gene and is associated with cytopenias and thrombosis. Although the trilineage of bone marrow elements is affected, involvement of the red blood cell (RBC) line was recognized first due to its abnormal sensitivity to complement-mediated intravascular hemolysis. Totally or partially deficient blood cell membrane proteins include decay accelerating factor (DAF, CD55), membrane inhibitor of reactive lysis (MIRL, CD59), and other proteins attached to the glycophosphatidylinositol (GPI) spine. Stem cell transplantation can be curative in PNH. Diverse laboratory abnormalities observed in PNH include bone marrow hyper- and hypoplasia, hematologic cytopenias, micro- and macrocytosis, decreased leukocyte alkaline phosphatase (LAP), hemoglobin- and hemosiderinuria, as well as associated iron deficiency. The more definitive laboratory tests comprise older biochemical and newer flow cytometric (FCM) procedures. The former group includes the sucrose hemolysis test for screening and Ham's acid hemolysis test for confirmation; the latter group includes FCM analyses of CD55 and CD59, which have recently replaced Ham's test, and FCM quantification of specific GPI-anchor binding using fluorescent-labeled inactive toxin aerolysin (FLAER). FLAER is more sensitive than FCM quantification of antibody-binding to CD59 for PNH diagnosis.
    Annals of clinical and laboratory science 02/2003; 33(4):401-6. DOI:10.1309/LMR59ZN0MFZMGQRB · 0.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disease with complex pathophysiology, characterized by a global deficiency in glycosyl-phosphatidylinositol-anchored proteins in the affected cells. The name of the condition emphasizes the occurrence of complement-induced hemolysis due to lack of essential complement regulatory proteins in erythrocytes, particularly CD59. Over time, it became apparent that episodic exacerbations of chronic hemolytic anemia are not necessarily nocturnal, nor do they represent the main presenting symptom in all cases. Paroxysmal nocturnal hemoglobinuria can also manifest with thrombotic events and bone marrow failure, and distinguishing among different types of PNH is important for treatment and prognostic purposes.
    Laboratory Medicine 08/2006; 37(8):498-502. DOI:10.1309/NAAH5J8DV43C0H7N · 0.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematopoietic stem cell disorder closely related to aplastic anemia. Hemolytic anemia and life-threatening thromboses are common features in many patients. Rapid diagnosis is highly desirable and flow cytometry plays a key role in the laboratory investigation of PNH. By demonstrating absence of cell membrane glycosylphosphatidylinositol-anchored proteins from granulocytes or red cells, a definitive diagnosis of PNH can be established. This can have a considerable impact on patient management and outcome. As with all rare diseases, internal and external quality assurance is essential for good laboratory practice and to fulfill the requirements of national laboratory accreditation schemes.
    Clinics in Laboratory Medicine 10/2007; 27(3):577-90, vii. DOI:10.1016/j.cll.2007.05.012 · 1.37 Impact Factor
Show more